Encorafenib plus binimetinib demonstrates favorable efficacy compared with other treatment option for patients with BRAF-mutated melanoma.

News

By Marilynn Larkin

NEW YORK (Reuters Health) – People who carry a BsmI single-nucleotide polymorphism (SNP) are twice as likely to develop nonmelanoma skin cancer (NMSC) as their peers with similar known risk factors, such as older age, male sex, and light eye and skin color, researchers say.

Read More

By Will Boggs MD

NEW YORK (Reuters Health) - Men who use phosphodiesterase type 5 (PDE5) inhibitors have a slightly increased risk of developing melanoma and basal cell carcinoma, according to a new meta-analysis.

Read More

By Marilynn Larkin

NEW YORK (Reuters Health) - Contrary to current guidelines, early melanoma patients under age 40 may be more suitable for sentinel lymph node biopsy (SLNB) than those over age 65, researchers in Pennsylvania suggest.

Read More

Research in Review

Ipilimumab (Yervoy; Bristol-Myers Squibb) combined with local peripheral treatments such as radiotherapy or electrochemotherapy may significantly prolong survival in patients with melanoma compared with ipilimumab alone, according to a retrospective clinical study published in Cancer Immunology Research.

Read More

Discontinuing nivolumab-ipilimumab treatment because of adverse events may not have a detrimental impact on survival among patients with advanced melanoma, according to follow-up from a randomized trial presented at the American Society of Clinical Oncology Annual Meeting (June 3-7, 2016; Chicago, IL).

Read More

Subscribe to Skin Cancer